Why Etsy Stock Is Trading Higher During Thursday’s After-Hours Session
Etsy (NASDAQ: ETSY) shares are trading higher after the company reported better-than-expected fourth-quarter EPS and sales results.
Why Desktop Metal Stock Is Trading Higher Today
Desktop Metal (NYSE: DM) shares are trading higher after the company announced it tripled manufacturing capacity for Production System P-50.
Why Benessere Capital Acquisition Corp Stock Is Trading Higher Today
Benessere Capital Acquisition (NASDAQ: BENE) shares are trading higher on abnormally-high volume in relation with Digital World Acquisition Corp (NASDAQ: DWAC).
Why Marqeta Stock Is Trading Higher Today
Marqeta (NASDAQ: MQ) shares are trading higher on above-average volume following a Citron Research tweet.
Why Creatd Stock Is Trading Higher Today
Creatd (NASDAQ: CRTD) shares are trading higher after the company announced a second NFT drop, which is a series of three photographs of former President Donald Trump.
Why PayPal Stock Is Trading Higher Today
PayPal (NASDAQ: PYPL) shares are trading higher after the company announced it is not pursuing an acquisition of Pinterest (NYSE: PINS) at this time.
Why Xiaobai Maimai Stock Is Trading Higher Today
Xiaobai Maimai (NASDAQ: HX) shares are trading higher on above-average volume. Not seeing any company-specific news from the session. The company on Tuesday disclosed the resignation of its CEO and Chairman and announced the appointment of Yilin Wang as CEO.
Why SeaSpine Stock Is Trading Lower Today
SeaSpine (NASDAQ: SPNE) shares are trading lower after the company announced due to uncertainties surrounding COVID-19, the company is unable to confirm its prior revenue guidance for the fourth quarter and full-year 2021 at this time.
Why Acceleron Pharma Stock Is Trading Higher Today
Acceleron Pharma (NASDAQ: XLRN) shares are trading higher after Bloomberg reported the company is in talks for a potential $11 billion buyout.
Why AstraZeneca Stock Is Trading Higher Today
AstraZeneca (NASDAQ: AZN) shares are trading higher after the company announced lynparza PROpel trial met the primary endpoint in metastatic castration-resistant prostate cancer.